New combo therapy aims to shrink rare melanomas before surgery
NCT ID NCT05546827
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether giving radiation therapy along with immunotherapy before surgery can improve outcomes for people with sinonasal or anorectal mucosal melanoma, two rare and aggressive cancers. About 40 participants will receive combination immunotherapy (such as ipilimumab with nivolumab) followed by radiation, then surgical removal of the tumor. The main goal is to see how many patients have a significant reduction or disappearance of the tumor after this pre-operative treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- combination immunotherapy (ipilimumab and nivolumab or nivolumab and relatlimab) and radiation therapy
- What this could lead to
- If successful, this approach could lead to better tumor control and fewer recurrences for patients with these rare and hard-to-treat melanomas.
- What could go wrong
- This is a small Phase 2 trial with only 40 participants, so results may not apply broadly. The combination of radiation and immunotherapy can cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANORECTAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States